Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024

Rhea-AI Summary

Vericel (NASDAQ:VCEL), a key player in advanced therapies for sports medicine and severe burn care, announced its participation in the Leerink Partners Healthcare Crossroads Conference. The event will take place on May 29, 2024, at 9:40 a.m. ET. Vericel's President and CEO, Nick Colangelo, along with CFO Joe Mara, will represent the company in a fireside chat. Investors and interested parties can access the webcast of the presentation through the Investor Relations section of the Vericel website.

Positive

• Vericel's inclusion in the Leerink Partners Healthcare Crossroads Conference enhances its visibility in the healthcare sector.
• Participation by high-level executives such as the CEO and CFO highlights Vericel's commitment to transparency and investor engagement.
• The webcast availability broadens access for investors unable to attend in person, potentially increasing investor interest and stock activity.

Negative

• No specific financial or clinical data updates were provided in this announcement, which may leave investors seeking more concrete information on business performance.
• The press release does not indicate any immediate impact on revenue or profitability, leaving the potential business impact uncertain.

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com

FAQ

When is Vericel presenting at the Leerink Partners Healthcare Crossroads Conference?

Vericel is presenting on May 29, 2024, at 9:40 a.m. ET.

Where can I watch the Vericel presentation at the Leerink Partners Healthcare Crossroads Conference?

You can watch the webcast of the presentation on the Investor Relations section of the Vericel website.

Who will represent Vericel at the Leerink Partners Healthcare Crossroads Conference?

Nick Colangelo, President and CEO, and Joe Mara, CFO, will represent Vericel.

What is the stock symbol for Vericel?

The stock symbol for Vericel is VCEL.